Table 2. Scenario-Based Affordability Assessment for Type 1 Diabetes .

Medication Therapy	Generic Name	Dose	Dosage Form	Dose of Administration/Day	Insurance Coverage (%)	Affordability Ratio
Monotherapy	Insulin regular human	100 IU/mL	Vial	40 IU	95	0.23
	Insulin regular human	100 IU/mL (3 mL)	Cartridge	40 IU	90	0.08
	Insulin aspart	100 IU/mL (3 mL)	Pen	40 IU	90	0.32
	Insulin aspart rapid	100 IU/mL (3 mL)	Pen	40 IU	90	0.32
	Insulin biphasic isophane 70+30	100 IU/mL (10 mL)	Vial	40 IU	95	0.02
	Insulin biphasic isophane	100 IU/mL (3 mL)	Cartridge	40 IU	90	0.08
	Insulin isophane	100 IU/mL (5 mL)	Vial	40 IU	70	0.27
	Insulin isophane (NPH) beef	100 IU/mL	Vial	40 IU	70	1.16
	Insulin isophane (NPH) human	1000 IU/10 mL	Vial	40 IU	95	0.23
	Insulin Isophane (NPH) Human	100 IU/mL (3 mL)	Cartridge	40 IU	90	0.08
	Insulin Glargine	300 IU/3 mL	Cartridge	40 IU	90	0.83
	Insulin Glargine	300 IU/3 mL	Pen	40 IU	90	0.96
	Insulin Glulisine	300 IU/3 mL	Vial	40 IU	70	2.29
	Insulin Lispro	100 IU/mL	Pen	40 IU	0	70.03
	Insulin Detemir	100 IU/mL	Injection	40 IU	70	3.45
Combination therapy (50% basal+ 50% rapid or short acting)	NPH + Regular	100 IU/mL	Isophane (Vial)	0.5 IU/kg/d	90	0.43
		100 IU/mL	Regular (Vial)	0.5 IU/kg/d	95
	NPH + Aspart	100 IU/mL	Isophane (Vial)	0.5 IU/kg/d	90	0.67
		100 IU/mL	Aspart (Pen)	0.5 IU/kg/d	95
	NPH + Glulisine	100 IU/mL	Isophane (Vial)	0.5 IU/kg/d	90	2.36
		100 IU/mL	Glulisine (Pen)	0.5 IU/kg/d	70
	Glargine + Regular	100 IU/mL	Glargine (Pen)	0.5 IU/kg/d	90	1.11
		100 IU/mL	Regular (Vial)	0.5 IU/kg/d	95
	Glargine + Aspart	100 IU/mL	Glargine (Pen)	0.5 IU/kg/d	90	1.34
		100 IU/mL	Aspart (Pen)	0.5 IU/kg/d	95
	Glargine + Glulisine	100 IU/mL	Glargine (Pen)	0.5 IU/kg/d	90	4.79
		100 IU/mL	Glulisine (Pen)	0.5 IU/kg/d	70

Note: The weight 75 kg was considered in calculations.